{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:28:43Z","timestamp":1740126523609,"version":"3.37.3"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.rmed.2024.107791","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T21:54:28Z","timestamp":1725832468000},"page":"107791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-9941","authenticated-orcid":false,"given":"Martina","family":"Koziar Va\u0161\u00e1kov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-7873","authenticated-orcid":false,"given":"Jakub","family":"Gregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrin","family":"Mogulkoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai R.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"\u0160terclov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-3187","authenticated-orcid":false,"given":"Veronika","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00f3bert","family":"Slivka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Studnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-3830","authenticated-orcid":false,"given":"Martina","family":"Pla\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"\u017durkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasna","family":"Tekavec-Trkanjec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Doubkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Ovesn\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/ajrccm.157.1.9704130","article-title":"Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis","volume":"157","author":"Bjoraker","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2024.107791_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1183\/23120541.00591-2021","article-title":"Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"8","author":"Zheng","year":"2022","journal-title":"ERJ Open Res"},{"issue":"22","key":"10.1016\/j.rmed.2024.107791_bib4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107791_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618800618","article-title":"Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience","volume":"12","author":"Rivera-Ortega","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12890-023-02450-3","article-title":"The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry","volume":"23","author":"\u0160tef\u00e1nikov\u00e1","year":"2023","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"10.1016\/j.rmed.2024.107791_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0897190017735242","article-title":"Nintedanib for idiopathic pulmonary fibrosis","volume":"32","author":"Tepede","year":"2019","journal-title":"J. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2024.107791_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12931-018-0907-8","article-title":"Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis","volume":"19","author":"Yoon","year":"2018","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2024.107791_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s12325-019-00906-9","article-title":"Long-term effects and adverse events of nintedanib therapy in idiopathic pulmonary fibrosis patients with functionally advanced disease","volume":"36","author":"Barczi","year":"2019","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.rmed.2024.107791_bib12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/resp.14116","article-title":"Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort","volume":"26","author":"Durheim","year":"2021","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.rmed.2024.107791_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262795","article-title":"Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: a single-center retrospective study","volume":"17","author":"Komatsu","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.rmed.2024.107791_bib14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107791_bib15","unstructured":"The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (ninth ed.). Boston: Little, Brown & Co. pp. 253-256."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1183\/23120541.00172-2019","article-title":"Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study","volume":"6","author":"Antoniou","year":"2020","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.rmed.2024.107791_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273854","article-title":"Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone","volume":"17","author":"M\u00e1jek","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.rmed.2024.107791_bib18","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/biomedicines10081973","article-title":"The effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis, familial pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world study","volume":"10","author":"Cameli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.rmed.2024.107791_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.581828","article-title":"Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study","volume":"7","author":"Cameli","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12325-020-01523-7","article-title":"Real-world study analysing progression and survival of patients with idiopathic pulmonary fibrosis with preserved lung function on antifibrotic treatment","volume":"38","author":"Noor","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2024.107791_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211023357","article-title":"The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: a multicenter retrospective study","volume":"9","author":"Dobashi","year":"2021","journal-title":"SAGE Open Med"},{"issue":"11","key":"10.1016\/j.rmed.2024.107791_bib22","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.21037\/jtd.2016.11.40","article-title":"Relationship between survival and age in patients with idiopathic pulmonary fibrosis","volume":"8","author":"Koo","year":"2016","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12931-019-1271-z","article-title":"The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis","volume":"21","author":"Tran","year":"2020","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2024.107791_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chest.2020.02.009","article-title":"Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study","volume":"158","author":"Zaman","year":"2020","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112400266X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112400266X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T22:32:36Z","timestamp":1732314756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112400266X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"alternative-id":["S095461112400266X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107791","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107791"}}